Arbidol, 20 pcs., 50 mg, film-coated tablets

What kind of medicine is Arbidol?

The drug Arbidol is a fairly effective antiviral agent.

The medication specifically affects viruses and provokes the production of interferon in the human body.

The active component of Arbidol helps stimulate the cellular, humoral reactions of the immune system, thereby increasing resistance to viral pathologies.

Due to the mechanism of action on the body, the medicine can be called a fusion inhibitor. Taking a pharmaceutical product helps:

• reducing the incidence of complications associated with exposure to viruses
• reduces the risk of exacerbation of chronic bacterial diseases

Arbidol powder for suspension 25mg/5ml 37g

A country

Russia
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.

Active substance

Umifenovir

Compound

Bottle 37 g
Umifenovir hydrochloride monohydrate 25.88 mg.

Excipients: sodium chloride - 26.85 mg, maltodextrin (Kleptose Linecaps) - 750 mg, sucrose (sugar) - 840.42 mg, colloidal silicon dioxide (Aerosil) - 24.6 mg, titanium dioxide - 25 mg, pregelatinized starch (type PA5PH) - 129.5 mg, sodium benzoate - 9.25 mg, banana flavor - 12.4 mg, cherry flavor - 6.1 mg. Powder for the preparation of a suspension for oral administration is granular, white or almost white in color, with a characteristic fruity odor. The prepared suspension is homogeneous, white or white with a yellowish or creamy tint, with a characteristic fruity odor.

pharmachologic effect

Antiviral agent. Specifically suppresses in vitro influenza viruses A and B (Influenza virus A, B), including highly pathogenic subtypes A(H1N1)pdm09 and A(H5N1), as well as other viruses that cause acute respiratory viral infections (coronavirus associated with severe acute respiratory syndrome (SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus)). According to the mechanism of antiviral action, it belongs to fusion inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. It has interferon-inducing activity - in a study on mice, the induction of interferons was noted after 16 hours, and high titers of interferons remained in the blood up to 48 hours after administration. Stimulates cellular and humoral immune responses: increases the number of lymphocytes in the blood, especially T-cells (CD3), increases the number of T-helpers (CD4) without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer (NK) cells. Therapeutic effectiveness for viral infections is manifested in a decrease in the duration and severity of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with viral infection and exacerbations of chronic bacterial diseases. Refers to low-toxic drugs (LD50>4 g/kg). Does not have any negative effects on the human body when administered orally in recommended doses.

Indications for use

— prevention and treatment of influenza A and B, other acute respiratory viral infections in children over 2 years of age and adults; — complex therapy of acute intestinal infections of rotavirus etiology in children from 2 years of age; — nonspecific prevention of severe acute respiratory syndrome (SARS) in children over 6 years of age and adults; - treatment of severe acute respiratory syndrome (SARS) in children over 12 years of age and adults.

Side effects

Allergic reactions: - rarely (with a frequency of at least 1/10,000, but less than 1/1000) - skin itching, rash, angioedema, urticaria; - very rarely (with a frequency of less than 1/10,000) - anaphylactic reactions. If any of the side effects indicated in the instructions get worse, or the patient notices any other side effects not listed in the instructions, he should inform the doctor.

Contraindications

- hypersensitivity to umifenovir or any component of the drug;
- age up to 2 years; — age up to 6 years (according to indications, nonspecific prevention of SARS); - age up to 12 years (according to indications for treatment of SARS). - sucrase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption. Use during pregnancy and breastfeeding The use of Arbidol® during pregnancy is contraindicated. It is not known whether the active substance of Arbidol® or its metabolites passes into breast milk in women during lactation. If it is necessary to use the drug Arbidol®, you should stop breastfeeding.

Use in children Contraindications:

- age up to 2 years; — age up to 6 years (according to indications, nonspecific prevention of SARS); - age up to 12 years (according to indications for treatment of SARS).

Mode of application

Inside, before meals. Preparation of the suspension Add 30 ml (or approximately up to 2/3 of the volume of the bottle) of water boiled and cooled to room temperature to the bottle containing the powder. Close the bottle with a lid, turn it upside down and shake thoroughly until a homogeneous suspension is obtained. Add boiled and cooled water to a volume of 100 ml (up to the mark on the bottle) and shake again. Before each dose, shake the contents of the bottle thoroughly until a homogeneous suspension is obtained. Measure a single dose using the included measuring spoon. Single dose (depending on age) Age | Single dose of the drug, ml suspension (mg umifenovir) from 2 to 6 years | 10 ml (50 mg) from 6 to 12 years | 20 ml (100 mg) over 12 years and adults | 40 ml (200 mg) Indication | Dosage regimen for children over 2 years of age and adults: Nonspecific prophylaxis during an epidemic of influenza and other acute respiratory viral infections | in a single dose 2 times a week for 3 weeks. Nonspecific prophylaxis in direct contact with patients with influenza and other acute respiratory viral infections | in a single dose 1 time/day for 10-14 days. Treatment of influenza and other acute respiratory viral infections with an uncomplicated course | in a single dose 4 times/day (every 6 hours) for 5 days. In children from 2 years of age: Complex therapy of acute intestinal infections of rotavirus etiology | in a single dose 4 times/day (every 6 hours) for 5 days. For nonspecific prevention and treatment of severe acute respiratory syndrome (SARS) For nonspecific prevention of SARS (in contact with a patient) in children from 6 years of age and adults: children from 6 to 12 years old - 20 ml (100 mg), children over 12 years old and adults - 40 ml (200 mg) 1 time/day for 12-14 days. For the treatment of SARS in children over 12 years of age and adults: children over 12 years of age and adults - 40 ml (200 mg) 2 times a day for 8-10 days.

special instructions

When prescribing to patients with diabetes mellitus, as well as on a low-calorie diet, it is necessary to take into account that the suspension contains sucrose (0.8 g/5 ml or 0.06 XE/5 ml). It is necessary to follow the regimen and duration of taking the drug recommended in the instructions. If you miss one dose of the drug, the missed dose should be taken as early as possible and continue the course of taking the drug according to the started regimen. When calculating the amount of suspension required for a course of administration, it is necessary to take into account the shelf life of the prepared suspension, which is 10 days. For a course of treatment indicated for nonspecific prophylaxis during an epidemic of influenza and other acute respiratory viral infections in children from 2 to 6 years old, two bottles of the drug Arbidol® will be required. Effect on the ability to drive vehicles and machinery Does not exhibit central neurotropic activity and can be used in medical practice by people of various professions, incl. requiring increased attention and coordination of movements (transport drivers, operators, etc.).

Overdose

Not marked.

Interaction with other drugs

When prescribed with other drugs, no negative effects were noted.

Indications for use

Most often, doctors recommend using Arbidol for the prevention and treatment of viral diseases.

The medicine is recommended for:

• influenza type A and B
• acute respiratory viral infection
• bronchitis, pneumonia (complex therapy)
• immunodeficiency
• severe acute respiratory disease

In addition, the medication is prescribed for:

• prevention of infectious diseases after surgery
• normalization of immunity

Doctors prescribe the drug to children under 3 years of age for intestinal infections of rotavirus etiology (complex treatment).

Instructions for use of Arbidol

• Both forms are taken orally before meals.
• The dosage of the capsule form depends on the age of the patient. For children from 3 to 6 years old, doctors prescribe 50 mg; for children from 6 to 12 years old, the dosage is doubled. Persons over 12 years of age can take 200 mg of the medication.
• Arbidol is not prescribed to children under 3 years of age.
• After contact with an infected patient, you can take Arbidol for preventive purposes for 2 weeks.
• In the above-mentioned dosage, the drug is prescribed during an epidemic of viral pathologies. In this situation, the medicine should be taken twice a week, one dose, the prophylactic course should last 3 weeks.
• Doctors prescribe the tablet form to children from 3 to 6 years old one tablet (50 mg), children from 6 to 12 years old are recommended to take 100 mg of the medicine, adult patients are advised to take 200 mg.
• Depending on the situation, the doctor can select the dosage of the medication individually for each patient.

Arbidol tablets

Registration number: LSR-003900/07

Trade name of the drug: Arbidol®

International nonproprietary name: Umifenovir

Chemical name: 6-Bromo-5-hydroxy-1-methyl-4-dimethylaminomethyl 2-phenylthiomethylindole-3-carboxylic acid ethyl ester hydrochloride monohydrate.

Dosage form: film-coated tablets.

Compound

One tablet contains: active ingredient: umifenovir hydrochloride monohydrate – 51.75 mg (in terms of umifenovir hydrochloride – 50.00 mg);

Excipients:

core: potato starch - 31.860 mg, microcrystalline cellulose - 57.926 mg, povidone (povidone K30) - 8.137 mg, calcium stearate - 0.535 mg, croscarmellose (croscarmellose sodium) - 1.542 mg;

shell:

Opadry 10F280003 White (Opadry 10F280003 WHITE) - 6,000 mg, [Hypromellose (hydroxypropyl methylcellulose 2910) - 3.54 mg, macrogol (polyethylene glycol) - 0.48 mg, polysorbate-80 (Tween-80) - 0.06 mg, titanium dioxide - 1.92 mg.

Description

Film-coated tablets from white to off-white with a creamy tint, round, biconvex. On the fracture it is white to white with a greenish-yellowish or creamy tint.

Pharmacotherapeutic group: antiviral agent.

ATX code: J05AX13

Pharmacological properties

Pharmacodynamics. Antiviral agent. Specifically suppresses in vitro influenza viruses A and B (Influenzavirus A, B), including highly pathogenic subtypes A(H1N1)pdm09 and A(H5N1), as well as other viruses that cause acute respiratory viral infections (ARVI) (coronavirus associated with severe acute respiratory syndrome (SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus)). According to the mechanism of antiviral action, it belongs to fusion inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. It has a moderate immunomodulatory effect and increases the body's resistance to viral infections. It has interferon-inducing activity - in a study on mice, the induction of interferons was noted after 16 hours, and high titers of interferons remained in the blood up to 48 hours after administration. Stimulates cellular and humoral immune responses: increases the number of lymphocytes in the blood, especially T cells (CD3), increases the number of T helper cells (CD4) without affecting the level of T suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases number of natural killer (NK) cells.

Therapeutic effectiveness for viral infections is manifested in a decrease in the duration and severity of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with viral infection and exacerbations of chronic bacterial diseases.

Refers to low-toxic drugs (LD50>4 g/kg). Does not have any negative effects on the human body when administered orally in recommended doses.

Pharmacokinetics. Quickly absorbed and distributed throughout organs and tissues. The maximum concentration in blood plasma when taken at a dose of 50 mg is achieved after 1.2 hours, at a dose of 100 mg - after 1.5 hours. Metabolized in the liver. The half-life is 17-21 hours. About 40% is excreted unchanged, mainly with bile (38.9%) and in small amounts by the kidneys (0.12%). During the first day, 90% of the administered dose is eliminated.

Indications for use

Prevention and treatment in adults and children: influenza A and B, other acute respiratory viral infections.

Complex therapy of acute intestinal infections of rotavirus etiology in children over 3 years of age.

Complex therapy of chronic bronchitis, pneumonia and recurrent herpes infection.

Prevention of postoperative infectious complications.

Contraindications

Hypersensitivity to umifenovir or any component of the drug, children under 3 years of age. First trimester of pregnancy.

Carefully

Second and third trimesters of pregnancy.

Use during pregnancy and breastfeeding

In animal studies, no harmful effects on pregnancy, embryonic and fetal development, labor or postnatal development were identified.

The use of Arbidol® in the first trimester of pregnancy is contraindicated. In the second and third trimester of pregnancy, Arbidol® can be used only for the treatment and prevention of influenza and if the expected benefit to the mother outweighs the potential risk to the fetus. The benefit/risk ratio is determined by the attending physician.

It is not known whether Arbidol® passes into breast milk in women during lactation. If you need to use Arbidol®, you should stop breastfeeding.

Directions for use and doses

Inside, before meals.

Single dose (depending on age):

The drug should be taken from the moment the first symptoms of influenza and other acute respiratory viral infections appear, preferably no later than 3 days from the onset of the disease.

If, after taking the drug Arbidol® for three days during the treatment of influenza and other acute respiratory viral infections, the severity of the symptoms of the disease, including high temperature (38 ° C or more), then you must consult a doctor to assess the validity of taking the drug.

Use the drug only according to the indications, method of administration and in the doses indicated in the instructions.

When treating influenza and ARVI, concomitant symptomatic therapy is possible, including taking antipyretic drugs, mucolytics and local vasoconstrictors.

Side effect

The drug Arbidol® is a low-toxic drug and is usually well tolerated.

Side effects are rare, usually mild or moderate and transient.

The frequency of adverse drug reactions is determined in accordance with the WHO classification: very often (with a frequency of more than 1/10), often (with a frequency of at least 1/100, but less than 1/10), infrequently (with a frequency of at least 1/1000, but less than 1/100), rare (with a frequency of at least 1/10,000, but less than 1/1000), very rare (with a frequency of less than 1/10,000), frequency unknown (cannot be determined from available data)

Immune system disorders: rarely - allergic reactions.

If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

Not marked.

Interaction with other drugs

When prescribed with other drugs, no negative effects were noted.

No special clinical studies have been conducted to study the interaction of the drug Arbidol® with other drugs.

There was no evidence of undesirable interactions with antipyretic, mucolytic and local vasoconstrictor drugs in a clinical study.

special instructions

It is necessary to follow the regimen and duration of taking the drug recommended in the instructions. If you miss taking one dose of the drug, the missed dose should be taken as early as possible and continue taking the drug according to the started regimen. If, after taking the drug Arbidol® for three days during the treatment of influenza and other acute respiratory viral infections, the severity of the symptoms of the disease, including high temperature (38 ° C or more), then you must consult a doctor to assess the validity of taking the drug.

Impact on the ability to drive vehicles and machinery

It does not exhibit central neurotropic activity and can be used in medical practice by people of various professions, incl. requiring increased attention and coordination of movements (transport drivers, operators, etc.).

Release form

Film-coated tablets, 50 mg.

10 tablets in a blister pack.

1, 2, 3 or 4 blister packs along with instructions for use in a cardboard pack.

Best before date

3 years.

Do not use after the expiration date stated on the packaging.

Storage conditions

At a temperature not higher than 25°C.

Keep out of the reach of children

Conditions for dispensing from pharmacies Dispensed without a prescription.

Marketing authorization holder/organization receiving consumer complaints

PJSC OTCPharm, Russia, 123317, Moscow, st. Testovskaya, 10 Tel. Fax

, 305022, Russia, Kursk, st. 2nd Aggregatnaya, 1a/18, tel./fax: (4712) 34-03-13

Is Arbidol suitable for breastfeeding women?

Arbidol is a low-toxic medicine. When using it, side effects are extremely rarely observed. Unfortunately, no experiments have been conducted regarding the effect of the drug on breastfeeding. The instructions note that it is unknown how much of the substance passes into breast milk. Therefore, it is more advisable to interrupt breastfeeding during treatment.

But still, some doctors prescribe the drug during lactation, until a negative effect on the child has been recorded.

Arbidol® (Arbidol®)

Antiviral agent. Specifically suppresses in
vitro
influenza viruses A and B
{ Influenzavirus A, B),
including highly pathogenic subtypes
A (
H1N1
) pdm 09
and
A ( H 5 N 1),
as well as other viruses that cause acute respiratory viral infections (ARVI) (coronavirus
{ Coronavirus ),
associated with severe acute respiratory syndrome (SARS), rhinovirus
{ Rhinovirus ),
adenovirus
{ Adenovirus ),
respiratory syncytial virus
( Pneumovirus )
and parainfluenza virus (
Paramyxovirus )).
According to the mechanism of antiviral action, it belongs to fusion inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. It has a moderate immunomodulatory effect and increases the body's resistance to viral infections. It has interferon-inducing activity - in a study on mice, the induction of interferons was noted after 16 hours, and high titers of interferons remained in the blood up to 48 hours after administration. Stimulates cellular and humoral immune responses: increases the number of lymphocytes in the blood, especially T-cells (CD3), increases the number of T-helpers (CD4) without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer (NK) cells.

Therapeutic effectiveness for viral infections is manifested in a decrease in the duration and severity of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with viral infection and exacerbations of chronic bacterial diseases.

In the treatment of influenza or ARVI in adult patients, a clinical study showed that the effect of the drug Arbidol® in adult patients is most pronounced in the acute period of the disease and is manifested by a reduction in the time for resolution of symptoms of the disease, a decrease in the severity of manifestations of the disease and a reduction in the time for elimination of the virus.

Therapy with Arbidol® leads to a higher frequency of relief of symptoms of the disease on the third day of therapy compared to placebo: 60 hours after the start of therapy, the resolution of all symptoms of laboratory-confirmed influenza is more than 5 times higher than the same indicator in the placebo group.

A significant effect of the drug Arbidol® on the rate of elimination of the influenza virus was established, which, in particular, was manifested by a decrease in the frequency of detection of viral RNA on the 4th day.

Refers to low-toxic drugs (LD50>4 g/kg). Does not have any negative effects on the human body when administered orally in recommended doses.

What is stronger Arbidol or Anaferon

The homeopathic remedy Anaferon is prescribed for colds; it is also suitable for strengthening the immune system. However, the drug does not have an antiviral effect. When treating pathologies, its use is effective only in the initial stages of the disease.

The drug Arbidol perfectly fights viruses, so in case of viral diseases it is better to opt for it, it is more effective.

Both medications are recommended to be taken together with other medications if a person suffers from a serious illness. But Anaferon and Arbidol are excellent for use for preventive purposes, as they do not harm the body.

Before starting to take Arbidol, it is recommended that you carefully read the instructions included with the drug.